Abstract
Lapatinib, a small molecule epidermal growth factor receptor EGFR and human epidermal growth factor receptor 2 (HER2) inhibitor is an effective radiosensitizer in preclinical studies. The primary objective of this phase I trial was to evaluate the toxicity of concomitant therapy with lapatinib and radiation patients with locally recurrent or chemotherapy-refractory, locally advanced breast cancer. As a secondary objective, we evaluated the impact of lapatinib on activation of receptor and downstream signal transduction pathways using serial tumor biopsies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
